Eli Lilly and Co (LLY) Stake Held by Bank of Stockton

Eli Lilly and Co (LLY) Stake Held by Bank of Stockton

Several other large investors have also recently made changes to their positions in LLY. First Command Financial Services Inc. raised its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of Eli Lilly and during the fourth quarter worth $136,000. Crestwood Advisors Group LLC purchased a new stake in shares of Eli Lilly and during the first quarter worth $179,000. Alpha Windward LLC raised its stake in shares of Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock worth $189,000 after buying an additional 44 shares during the last quarter. Finally, Moloney Securities Asset Management LLC purchased a new stake in shares of Eli Lilly and during the first quarter worth $202,000. Institutional investors and hedge funds own 75.15% of the company’s stock.

Bank of Stockton held its stake in shares of Eli Lilly and Co (NYSE:LLY) during the first quarter, Holdings Channel reports. The firm owned 4,500 shares of the company’s stock at the end of the first quarter. Bank of Stockton’s holdings in Eli Lilly and were worth $377,000 at the end of the most recent quarter.

Shares of Eli Lilly and Co (NYSE LLY) traded up 1.56% during trading on Wednesday, reaching $79.57. 5,167,641 shares of the company’s stock were exchanged. The firm has a market capitalization of $84.05 billion, a PE ratio of 38.48 and a beta of 0.30. The company’s 50-day moving average price is $80.88 and its 200 day moving average price is $78.41. Eli Lilly and Co has a 52 week low of $64.18 and a 52 week high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.02. The company had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.22 billion. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the business earned $0.83 earnings per share. Analysts predict that Eli Lilly and Co will post $4.12 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 9th. Shareholders of record on Monday, May 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, May 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.61%. Eli Lilly and’s payout ratio is presently 80.62%.

LLY has been the topic of several research analyst reports. Vetr lowered shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $74.30 price target on the stock. in a research note on Tuesday, January 31st. BMO Capital Markets reiterated a “market perform” rating and set a $73.00 price target (up from $70.00) on shares of Eli Lilly and in a research note on Wednesday, February 1st. Barclays PLC lifted their price target on shares of Eli Lilly and from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, February 1st. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research note on Friday, February 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of Eli Lilly and in a research note on Friday, February 17th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Buy” and an average price target of $87.59.

In other Eli Lilly and news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the completion of the transaction, the senior vice president now directly owns 114,217 shares of the company’s stock, valued at $9,452,598.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $84.67, for a total value of $17,780,700.00. Following the transaction, the insider now directly owns 124,690,804 shares of the company’s stock, valued at $10,557,570,374.68. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LLY”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Related posts

Leave a Comment